COCP
Income statement / Annual
Last year (2024), Cocrystal Pharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Cocrystal Pharma, Inc.'s net income was -$17.50 M.
See Cocrystal Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.01 M |
$6.56 M |
$0.00 |
$0.00 |
$0.00 |
$78.00 K |
| Cost of Revenue |
$12.54 M
|
$15.17 M
|
$12.39 M
|
$8.79 M
|
$6.03 M
|
$4.00 M
|
$50.00 K
|
$101.00 K
|
$201.00 K
|
$192.00 K
|
| Gross Profit |
-$12.54 M
|
-$15.17 M
|
-$12.39 M
|
-$8.79 M
|
-$4.02 M
|
$2.56 M
|
-$50.00 K
|
-$101.00 K
|
-$201.00 K
|
-$114.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
-2
|
0.39
|
0
|
0
|
0
|
-1.46
|
| Research and Development Expenses |
$12.54 M
|
$15.17 M
|
$12.39 M
|
$8.79 M
|
$6.03 M
|
$4.00 M
|
$58.57 M
|
$5.82 M
|
$101.68 M
|
$47.26 M
|
| General & Administrative Expenses |
$5.34 M
|
$5.99 M
|
$5.75 M
|
$5.43 M
|
$5.57 M
|
$4.86 M
|
$4.35 M
|
$2.44 M
|
$4.14 M
|
$6.77 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.34 M
|
$5.99 M
|
$5.75 M
|
$5.43 M
|
$5.57 M
|
$4.86 M
|
$4.35 M
|
$2.44 M
|
$4.14 M
|
$6.77 M
|
| Other Expenses |
-$12.54 M
|
-$17.77 M
|
$8.30 M
|
-$8.79 M
|
-$6.03 M
|
$42.10 M
|
$0.00
|
-$131.00 K
|
-$1.00 K
|
$0.00
|
| Operating Expenses |
$5.34 M
|
$3.39 M
|
$26.44 M
|
$5.43 M
|
$5.57 M
|
$50.97 M
|
$62.92 M
|
$8.26 M
|
$105.82 M
|
$54.03 M
|
| Cost And Expenses |
$17.88 M
|
$18.56 M
|
$38.83 M
|
$14.22 M
|
$11.60 M
|
$54.97 M
|
$62.92 M
|
$8.26 M
|
$105.82 M
|
$54.03 M
|
| Interest Income |
$537.00 K
|
$640.00 K
|
$2.00
|
$4.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$126.00 K
|
$180.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$2.00 K
|
$4.00 K
|
$8.00 K
|
$19.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$126.00 K
|
$189.00 K
|
$185.00 K
|
$190.00 K
|
$157.00 K
|
$98.00 K
|
$50.00 K
|
$101.00 K
|
$201.00 K
|
$192.00 K
|
| EBITDA |
-$17.75 M |
-$20.97 M |
-$17.95 M |
-$14.03 M |
-$9.43 M |
-$2.21 M |
-$62.52 M |
-$7.39 M |
-$105.62 M |
-$53.76 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-4.68
|
-0.34
|
0
|
0
|
0
|
-689.18
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-4.76
|
-7.37
|
0
|
0
|
0
|
-691.64
|
| Total Other Income/Expenses Net |
$374.00 K
|
$575.00 K
|
-$8.00 K
|
$36.00 K
|
-$62.00 K
|
$237.00 K
|
$294.00 K
|
$769.00 K
|
$1.55 M
|
-$11.42 M
|
| Income Before Tax |
-$17.50 M
|
-$17.98 M
|
-$38.84 M
|
-$14.19 M
|
-$9.65 M
|
-$48.17 M
|
-$62.63 M
|
-$7.49 M
|
-$104.27 M
|
-$65.37 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-4.79
|
-7.34
|
0
|
0
|
0
|
-838.08
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$13.58 M
|
-$6.88 M
|
-$29.39 M
|
-$15.25 M
|
| Net Income |
-$17.50 M
|
-$17.98 M
|
-$38.84 M
|
-$14.19 M
|
-$9.65 M
|
-$48.17 M
|
-$49.05 M
|
-$613.00 K
|
-$74.87 M
|
-$50.12 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-4.79
|
-7.34
|
0
|
0
|
0
|
-642.59
|
| EPS |
-1.72 |
-0.0019 |
-4.77 |
-1.85 |
-2.01 |
-15.78 |
-21.01 |
-0.3 |
-38.17 |
-28.6 |
| EPS Diluted |
-1.72 |
-0.0019 |
-4.77 |
-1.85 |
-2.01 |
-15.78 |
-21.01 |
-0.3 |
-38.14 |
-28.6 |
| Weighted Average Shares Out |
$10.17 M
|
$9.65 M
|
$8.14 M
|
$7.69 M
|
$4.80 M
|
$3.05 M
|
$2.33 M
|
$2.01 M
|
$1.96 M
|
$1.75 M
|
| Weighted Average Shares Out Diluted |
$10.17 M
|
$9.65 M
|
$8.14 M
|
$7.69 M
|
$4.80 M
|
$3.05 M
|
$2.33 M
|
$2.01 M
|
$1.96 M
|
$1.75 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
